# THE VACCINE SCHEDULE 1950-2018

Nelson Branco, MD, FAAP Tamalpais Pediatrics, Larkspur CA

## The first vaccine – Smallpox

- Invented by Edward Jenner in 1796
  - Jenner noticed that milkmaids who were exposed to cowpox, a milder disease similar to smallpox, did not develop smallpox to the same extent as others
  - He developed method of arm-to-arm inoculation: a small amount of pus from one person's blisters was inoculated into the arm of another

#### Late 1940's

- In the early part of the century, scientific progress had allowed for the development of new vaccines and large scale vaccine production
- Recommended vaccines:
  - DTP (Diptheria, Tetanus, Pertussis)
  - Smallpox

### Late 1950's

Oral Polio Vaccine (OPV) – licensed in 1955

Recommended vaccines:

- DTP (Diphtheria, Tetanus, Pertussis)
- Smallpox
- Polio (OPV)

#### Late 1960's

- Vaccines against Measles (1963), Mumps (1967) and Rubella (1969) were developed
- Recommended vaccines:
  - DTP (Diphtheria, Tetanus, Pertussis)
  - Smallpox
  - Polio (OPV)
  - Measles
  - Mumps
  - Rubella

# 1970's

- Smallpox was declared eradicated and use of smallpox vaccine was discontinued in 1972
- Measles, Mumps, Rubella vaccine was combined into MMR
- Recommended vaccines:
  - DTP (Diphtheria, Tetanus, Pertussis)
  - Polio (OPV)
  - MMR (Measles, Mumps, Rubella)

#### 1985-1994

Hib vaccine developed and added to the schedule

Recommended vaccines:

- DTP (Diphtheria, Tetanus, Pertussis)
- Polio (OPV)
- MMR (Measles, Mumps, Rubella)
- Hib (Haemophilius influenzae Type B)

#### 1994-1995

- Hepatitis B was added to the schedule as a routine vaccination instead of being used only for high risk groups
- Recommended vaccines:
  - DTP (Diphtheria, Tetanus, Pertussis)
  - Polio (OPV)
  - MMR (Measles, Mumps, Rubella)
  - Hib (Haemophilius influenzae Type B)
  - Hepatitis B

Vaccine	Birth	2 Months	4 Months	6 Months	12 Months	15 Months	18 Months	4-6 Years	11-12 Years	14-16 Years
	HB-1									
Hepatitis B		HB-2		HB-3						
Diphtheria-Tetanus- Pertussis (DTP)		DTP	DTP	DTP		TP aP≥at15	months	DTP or DTaP	Td	
Haemophilus influenzae type b		Hib	Hib	Hib	H	lib				
Poliovirus		OPV	OPV	OPV				OPV		
Measles-Mumps- Rubella					M	ИR		MMR 🖸	m MMR	

FIGURE 1. Recommended childhood immunization schedule\* — United States, July-December 1996

						Age					
Vaccine	Birth	1 Mo.	2 Mos.	4 Mos.	б Mos.	12 Mos.	15 Mos.	18 Mos.	4б Yrs.	1112 Yrs.	1416 Yrs.
Hepatitis B†	Hep:B:1										
		<b>160 B</b> .2	<b>I</b>		Hep 8-3					Heo B	
Dipitheria and tetanus toxoids and pertussis vaccine 1			DTP	DTP	DTP	DTP (DTa	R⊇tŏnes		DTP or DTaP	<u>Ta</u>	
Haemophilus initienzae type b <sub>*</sub>			Hib	Hib	Нib						
Poliovirustt			OPV	OPV	::0 <b>P</b> 4:::				OPV		
Meastes-mumps- rubella#									MMR C	r MMR	
Variodia zoster Virus¶							Mar			Xar	



Range of Acceptable Ages for Vaccination

"Catch Up" Vaccination

FIGURE 1. Recommended childhood immunization schedule\* — United States, January-December 1999

						Age					
Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	12 mos	15 mos	18 mos	4—6 угs	11—12 улз	14-11 yrs
Hepatitis B <sup>†</sup>	Hep B										
			Hep B		Hep B					Hep B	
Diph theria and tetan ustoxoids an d pertussřs			DTaP	DTaP	DTaP		DI	aP	DTaP	Td	
H. influenzae type b <sup>1</sup>			Hib	Hib	Hib		ib				
Poliovirus##			IPV	IPV		P¢	lio		Polio		
Rotavirus#			Rv	Rv	Rv						
Measles-mumps- rubella <sup>#</sup>						M	MR		MMR	MMB	
Varicella <sup>11</sup>							Var			Var	




\_\_\_\_1

Vaccines to be Assessed and Administered if Necessary

Incorporation of this new vaccine into clinical practice may require additional time and resources from health-care providers.

FIGURE 1. Recommended childhood immunization schedule\* — United States, January-December 2000

Rotavirus vaccine removed from the schedule



Vaccines to be given if previously recommended doses were missed or were given earlier than the recommended minimum age. mended in selected states and/or regions.

On October 22, 1999, the Advisory Committee on Immunization Practices (ACIP) recommended that Rotashield<sup>®</sup> (rhesus rotavirus vaccine-tetravalent (RRV-TVI), the only U.S.-licensed rotavirus vaccine, no longer be used in the United States (*MMWR*, Vol. 48, No. 43, No. 43, No. 43, No. 43, No. 41, No. 41, No. 42, No. 44, No. 44

\* This schedule indicates the recommended ages for routine administration of licensed childhood vaccines as of November 1, 1999. Any dose not given at the recommended age should be given as a "catch-up" vaccination at any subsequent visit when indicated and feasible. Additional vaccines may be licensed and recommended uping the yacc. Licensed combination are indicated and recommended uping the yacc. Licensed combination vaccines may be used whenever any components of the combination are indicated and the vaccine's other components are not contraindicated. Providers should consult the manufacturers package inserts for detailed recommendations, second box school be administered at least 1 month after the first dose school be administered at least 1 month after the first dose and a least 2 months after the second dose, but not before age 6 months. Infants born to HBAAppositive mothers altowed at age 1-2 months and the first dose at age 6 months. Infants born to HBAAppositive mothers altowed the JBAA of third dose at age 6 months. Infants born to HBAAppositive mothers altowed the JBAA of third dose at age 6 months. Infants born to moths after the Second dose, but not before age 6 months. Infants born to HBAAppositive mothers altowed the combined at age 1-2 months and the third dose at age 6 months. Infants born to moths and the first dose at age 6 months. Infants born to moths and the first dose at age 6 months. Infants born to moths and the third dose tracement of the HBA of the HBA of the HBA of the third dose is recommended at age 1-2 months and the third dose tracement of the HBA of the HBA of the HBA of the till solutive, the infant should receive HBB at local the local at age 1-2 months and the third dose tracement of the HBA of the the HBA of the virus infection is moderately or highly endemic. e fourth dose of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) can be administered as early as age 12 months, provided

<sup>1</sup>The fourth dose of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTAP) can be administered as early as age 12 months, provided at age 11–12 years if at least 5 years have elapsed since the last dose of diphtheria and tetanus toxoids and pertussis vaccine (DTP). DTAP, or diphtheria and tetanus toxoids and pertussis vaccine (DTP), DTAP, or diphtheria and tetanus toxoids and pertussis vaccine (DTP), DTAP, or diphtheria and tetanus toxoids and pertussis vaccine (DTP), DTAP, or diphtheria and tetanus toxoids and pertussis vaccine (DTP), DTAP, or diphtheria and tetanus toxoids and pertussis vaccine (DTP), DTAP, or diphtheria and tetanus toxoids and pertussis vaccine (DTP), DTAP, or diphtheria and tetanus toxoids and pertussis vaccine (DTP), DTAP, or diphtheria and tetanus toxoids and pertussis vaccine (DTP), DTAP, or diphtheria and tetanus toxoids and pertussis vaccine (DTP), DTAP, or diphtheria and tetanus toxoids and pertussis vaccine (DTP), DTAP, or diphtheria and tetanus toxoids and toxoids and pertussis vaccine (DTP), DTAP, or diphtheria and tetanus toxoids and pertussis and the diphtheria toxoids and pertussis vaccine (DTP), DTAP, or diphtheria and tetanus toxoids and pertussis and toxoids and pertussis and toxoids and pertussis and that using some combinalization products should not be used for primary vaccination in infants at age 2, 4, or 6 months unless approved by the Food and Drug Administration for these ages. As To eliminate the risk for vaccine-associated paralytic policivity vaccine (DPV) if available and y builts of the following special circumstances: 1) mass vaccination campaigns to control outbreaks of paralytic policivity vaccine diphtheria age 2 months, and between ages 4 and 8 years. Cral policivity vaccine (DPV) if available and y builts of the following special circumstances: 1) mass vaccination campaigns to control outbreaks of paralytic policivity. Reveal and the divert of the divertion health-campaigns to control outbreaks of paralytic policivity. Reveal and the div accept the recommended number of vaccine injections may receive OPV only for the third or fourth dose or both; in this situation, health-care providers should administer OPV only after discussing the risk for VAPP with parents or caregivers. During the transition to an all-PV schedule, recommendations for the use of remaining OPV supplies in physicians' offices and clinics have been issued by the American Academy of Pediatrics (Pediatrics, Vol. 104, Not state of the No. 6. December 1999)

The second does of measles, mumps, and rubella vaccine (MMR) is recommended routinely at age 4–6 years but may be administered during any visit, provided at least 4 weeks have elapsed since receipt of the first dose and that both doses are administered beginning at or after age 12 months. Those who previously have not received the second dose should complete the schedule no later than the routine visit to a health-care provider at age 11-12 years. Varicella (Vari vaccine is recommended at any visit on or after the first birthday for susceptible children, i.e., those who lack a reliable history of chickenpox (as judged by a health-care provider) and who have not been vaccinated. Susceptible prosons aged >12 years should receive two doses given at least

A weeks apart.
 A weeks apart.
 Hepatitis A vaccine (Hep A) is recommended for use in selected states and regions. Information is available from local public health authorities and MMWR, Vol. 48, No. RR-12, October 1, 1999.

Use of trade names and commercial sources is for identification only and does not constitute or imply endorsement by CDC or the U.S. Department of Health and Human Services.

Source: Advisory Committee on Immunization Practices (ACIP), American Academy of Family Physicians (AAFP), and American Academy of Pediatrics (AAP)

	Ran	ge of reco	mmended a	ges		Catch-up	vaccinatio	n ////	P	readolesce	ent assessr	nent
Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	12 mos	15 mos	18 mos	24 mos	4–6 yrs	11–12 yrs	13–1 yrs
Hepatitis B"	Hep B #1	only if moth	er HBsAg (• )							Hep B	series	999
-			Hep B #2			Hep	B #3			1		
Diphtheria, Tetanus, Pertussis''			DTaP	DTaP	DTaP		רס	ĩaP		DTaP	Td	
<i>Haemophilus influenzae</i> Type b <sup>®</sup>			НіЬ	НіЬ	Hib	н	ib					
Inactivated Polio**			IPV	IPV		IP	v		J	IPV		
Measles, Mumps, Rubella						мм	R #1			MMR #2	MM	R #2
Varicella <sup>=</sup>							Varicella			Varie	cella 🚧	444
Pneumococcal			PCV	PCV	PCV	PC	cv		PC	V 💋 РІ	PV	
	s below this	line are for	selected po	pulations				~				
Hepatitis A***										Hepatitis	A series	
Influenza								Influenz	a (yearly)			

\* Indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2001, for children through age 18 years. Any dose not given at the recommended age should be given at any subsequent visit when indicated and feasible. Employing the indicates age groups that warrant special effort to administer those vaccines not given previously. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and the vaccine's other components are not contraindicated. Providers should consult the manufacturers' package inserts for detailed recommendations.

Hepatitis B vaccine (Hep B). All infants should receive the first does of hepatitis B vaccine scon after birth and before hospital discharge; the first does also may be given by age 2 months if the infant's mother is HBsAg-negative. Only monovalent hepatitis B vaccine can be used for the birth dose. Monovalent or combination vaccine containing Hep Bary be used to complete the series; 4 doese of vaccine may be administered if combination vaccine is used. The second dose should be given at least 4 weeks after the first dose except for HIb-containing waccine, which cannot be administered before age 6 weeks. The third dose should be given at least 16 weeks after the first dose except for HIb-containing waccine, which cannot be administered before age 6 weeks. The third dose build be given at least 16 weeks after the first dose end at least 3 weeks after the second dose. The last dose in the vaccination series (third of rourd dose) should be the administered before age 6 weeks. The third dose borne age 5 with a second dose is not hepatitis B vaccine and at least 3 and 12 and 10 to be administered before age 6 the second dose is recommended at age 1-2 months and the vaccination series should be completed (third for forth dose) should be diaven at het wacks after the first dose or hepatitis B vaccine and 0.5 mL hepatitis B immune globulin (HBIG) within 12 hours of birth at separate sites. The second dose is recommended at age 1-2 months and the vaccination series should be circle at a second mode. <u>Infants born to methang status is unknown</u> should neckive the first dose of the hepatitis B vaccine series within 12 hours of birth. Maternal blood should be drawn at the time of delivery to determine the mother's HBsAg status; if the HBsAg test is positive, the infant should receive the first dose is no and se is con as soon as possible (no later than a ge 1 tweek).


g Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). The fourth dose of DTaP may be administered as early as age 12 months provided that 6 months have elapsed since the third dose and the child is unlikely to return at age 15–18 months. Tetanus and diphtheria toxoids (Td) is recommended at age 11–12 years if at least 5 years have elapsed since the last dose of tratunus and diphtheria toxoid-containing vaccine. Subsequent routine Td dosetrar as recommended every 10 years.

1 Haemophilus influenzae type b (Hib) conjugate vaccine. Three Hib conjugate vaccines are licensed for infant use. If PRP-OMP (PedvaxHiB<sup>®</sup> or ComVax<sup>®</sup> [Merck]) is administered at age 2 and 4 months, a dose at age 6 months is not required. DTaP/Hib combination products should not be used for primary immunization in infants at age 2, 4 or 6 months but can be used as boosters following any Hib vaccine.

- \* Inactivated pollovirus vaccine (IPV). An all-IPV schedule is recommended for routine childhood poliovirus vaccination in the United States. All children should receive 4 doses of IPV at age 2, 4, and 6–18 months, and 4–6 years.
- HT Measles, mumps, and rubella vaccine (MMR). The second dose of MMR is recommended routinely at age 4–6 years but may be administered during any visit provided at least 4 weeks have elapsed since the first dose and that both doses are administered beginning at or after age 12 months. Those who have not previously received the second dose should complete the schedule by the visit at a a 11–12 years.
- % Varicella vaccine. Varicella vaccine is recommended at any visit, at or after age 12 months for susceptible children (i.e., those who lack a reliable history of chickenpox) Susceptible persons aged 213 years should receive 2 doses given at least 4 weeks apart.
- 19 Pneumococcal vaccine. The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for all children aged 2--23 months and for certain children aged 24--59 months. Pneumococcal polysaccharlde vaccine (PPV) is recommended in addition to PCV for certain high-risk groups. See MMWR 2000;49(No. RR-9):1--37.
- \*\*\* Hepatitis A vaccine. Hepatitis A vaccine is recommended for use in selected states and regions, and for certain high-risk groups. Consult local public health authority and MMWR 1999;48(No. RR-12):1–37.
- H: Influenza vaccine. Influenza vaccine is recommended annually for children aged \_6 months with certain its factors (including but not limited to asthma, cardiac disease, sickle cell disease, HV, and diabetes: see MMW7400150(No.ER-4)[-44], and carb be daministered to all others wishing to obtain immunity. Children aged \_12 spears should receive vaccine in a dosage appropriate for their age (0.25 mL if ~35 months or 0.5 mL if ~3 years). Children aged \_6 years who are receiving influenza vaccine for the first time should receive 2 does separated by at least 4 weeks.

Additional information about vaccines, vaccine supply, and contraindications for immunization is available at http://www.cdc.gov/nip or at the National Immunization hostine, 800-232-2522 (fighting), or 800-232 (233) (Sparish), Copies of the schedule can be obtained at http://www.dag.ov/nip/excibil/schedule.htm. Approved by Committee on Immunization Practices (http://www.cdc.gov/nip/acip), the American Academy of Pediatrics (http://www.asp.org), and the American Academy of Family Physicians (http://www.asp.org).

FIGURE. Recommended childhood and adolescent immunization schedule, by vaccine and age - United States, 2006



This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2005, for children through age 18 years. Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Indicates age groups that warrant special effort to administer those vaccines not previously administered Additional vaccines might be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination

Range of recommended ages

are indicated and other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult respective Advisory Committee on Immunization Practices (ACIP) statements for detailed recommendations. Clinically significant adverse events that follow vaccination should be reported through the vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at http://www.vaers.hhs.gov or by telephone, 800-822-796

Catch-up immunization

Assessment at age 11–12 years

- 1. Hepatitis B vaccine (HepB). AT BIRTH: All newborns should receive monovalent HepB soon after birth and before hospital discharge. Infants born to mothers who are hepatitis B surface antigen (HBsAg)-positive should receive HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth. Infants born to mothers whose HBsAg status is unknown should receive HepB within 12 hours of birth. The mother should have blood drawn as soon as possible to determine her HBsAg status; if HBsAg-positive, the infant should receive HBIG as soon as possible (no later than age 1 week). For infants born to HBsAg-negative mothers, the birth dose can be delayed in rare circumstances but only if a physician's order to withhold the vaccine and a copy of the mother's original HBsAgnegative laboratory report are documented in the infant's medical record FOLLOWING THE BIRTH DOSE: The HepB series should be completed with either monovalent HepB or a combination vaccine containing HepB. The second dose should be administered at age 1-2 months. The final dose should be administered at age ≥24 weeks. Administering four doses of HepB is permissible (e.g., when combination vaccines are administered after the birth dose); however, if monovalent HepB is used, a dose at age 4 months is not needed. Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of the HepB series at age 9-18 months (generally at the next well-child visit after completion of the vaccine series).
- 2. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose and the child is unlikely to return at age 15–18 months. The final dose in the series should be administered at age ≥4 years, Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap adolescent preparation) is recommended at age 11-12 years for those who have completed the recommended childhood DTP/DTaP vaccination series and have not received a tetanus and diphtheria toxoids (Td) booster dose Adolescents aged 13-18 years who missed the age 11-12-year Td/Tdap booster dose should also receive a single dose of Tdap if they have completed the recommended childhood DTP/DTaP vaccination series. Subsequent Td boosters are recommended every 10 years.
- Haemophikus influenzae type b conjugate vaccine (Hib). Three Hib conjugate vaccines are licensed for infant use. If PRP-OMP (PedvaxHIB® or ComVax® [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required. DTaP/Hib combination products should not be used for primary immunization in infants at ages 2, 4, or 6 months but may be used as boosters after any Hib vaccine. The final dose in the series should be administered at age >12 months.
- 4. Measles, mumps, and rubella vaccine (MMR). The second dose of MMR is recommended routinely at age 4-6 years but may be administered during any visit, provided at least 4 weeks have elapsed since the first dose and both doses are administered at or after age 12 months. Children who have not previously received the second dose should complete the schedule by age 11-12 years.

5. Varicella vaccine. Varicella vaccine is recommended at any visit at or after age 12 months for susceptible children (i.e., those who lack a reliable history of varicella Susceptible persons aged ≥13 years should receive 2 doses administered at least 4 weeks apart.

- Meningococcal vaccine (MCV4). Meningococcal conjugate vaccine (MCV4) should be administered to all children at age 11-12 years as well as to unvaccinated adolescents at high school entry (age 15 years). Other adolescents who wish to decrease their risk for meningcocccal disease may also be vaccinated. All college freshmen living in dormitories should also be vaccinated, preferably with MCV4. although meningococcal polysaccharide vaccine (MPSV4) is an acceptable alternative. Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and for certain other high risk groups (see MMWR 2005;54[No. RR-7]); use MPSV4 for children aged 2-10 years and MCV4 for older children, although MPSV4 is an acceptable alternative.
- 7. Pneumococcal vaccine. The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for all children aged 2-23 months and for certain children aged 24-59 months. The final dose in the series should be administered at age >12 months. Pneumococcal polysaccharide vaccine (PPV) is recommended in addition to PCV for certain high-risk groups. See MMWR 2000;49(No. RR-9). Influenza vaccine, Influenza vaccine is recommended annually for children aged
- ≥6 months with certain risk factors (including, but not limited to, asthma, cardiac disease, sickle cell disease, human immunodeficiency virus infection, diabetes and conditions that can compromise respiratory function or handling of respiratory secretions or that can increase the risk for aspiration), health-care workers, and other persons (including household members) in close contact with persons in groups at high risk (see MMWR 2005;54[No, RR-9]). In addition, healthy children aged 6-23 months and close contacts of healthy children aged 0-5 months are recommended to receive influenza vaccine because children in this age group are at substantially increased risk for influenza-related hospitalizations. For healthy nonpregnant persons aged 5-49 years, the intranasally administered, live, attenuated influenza vaccine (LAIV) is an acceptable alternative to the intramuscular trivalent inactivated influenza vaccine (TIV). See MMWR 2005;54(No. RR-8). Children receiving TIV should be administered an age-appropriate dosage (0.25 mL for children aged 6–35 months or 0.5 mL for children aged ≥3 years). Children aged <8 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by at least 4 weeks for TIV and at least 6 weeks for LAIV). Hepatitis A vaccine (HepA). HepA is recommended for all children at age 1 year (i.e., 12–23 months). The 2 doses in the series should be administered at least 6
- months apart. States, counties, and communities with existing HepA vaccination programs for children aged 2-18 years are encouraged to maintain these programs. In these areas, new efforts focused on routine vaccination of children aged 1 year should enhance, not replace, ongoing programs directed at a broader population of children. HepA is also recommended for certain high risk groups (see MMWR 1999;48[No. RR-12]).

The Childhood and Adolescent Immunization Schedule is approved by the Advisory Committee on Immunization Practices (http://www.cdc.gov/nip/acip), the American Academy of Pediatrics (http://www.aap.org), and the American Academy of Family Physicians (http://www.aafp.org)

FIGURE 1. Recommended immunization schedule for persons aged 0-6 years - United States, 2007

Vaccine ▼ Age ►	Birth	1 month	2 months	4 months	6 months	12 months	15 months	18 months	19-23 months	2–3 years	4–6 years	
Hepatitis B <sup>1</sup>	HepB	He	рВ	See footnote 1		He	рВ		H	lepB Seri	es	_
Rotavirus <sup>2</sup>			Rota	Rota	Rota							
Diphtheria, Tetanus, Pertussis <sup>o</sup>			DTaP	DTaP	DTaP		DT	aP			DTaP	Range of recommended
Haemophilus influenzae type b <sup>4</sup>			Hib	Hib	Hib⁴	H	ib		H	lib		ages
Pneumococcal <sup>s</sup>			PCV	PCV	PCV	P	CV			PCV	PV	
Inactivated Poliovirus			IPV	IPV		IF	V				IPV	Catch-up immunization
Influenza <sup>6</sup>							Influer	nza (Year	y)			ininani2auon
Measles, Mumps, Rubella <sup>7</sup>						M	MR				MMR	-
Varicella <sup>8</sup>			[			Vari	cella	[			Varicella	Certain
Hepatitis A <sup>9</sup>							HepA (	2 doses)		HepA	Series	high-risk
Meningococcal <sup>10</sup>										MP	SV4	groups

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for childhen aged 0–4 years. Additional information is available at http://www.cdc.gov/hip/necd/child-orhodule.htm. Any dose not administered at the recommended age should be administered at any subdequert visit, when indicated and feasible. Additional vaccines may be leared and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components of the combination are indicated and other components.

#### 1. Hepatitis B vaccine (HepB). (Minimum age: birth)

- At birth:
- Administer monovalent HepB to all newborns before hospital discharge.
   If mother is hepatitis surface antigen (HBsAg)-positive, administer HepB and 0.5 mL of hepatitis Bimmune olobulin (HBIG) within 12 hours of birth.
- If mother's HBsAg status is unknown, administer HepB within 12 hours of birth.
   Determine the HBsAg status as soon as possible and if HBsAg-positive, administer HBIS (no later than age 1 week).
- If mother is HBsAg-negative, the birth dose can only be delayed with physician's order and mothers' negative HBsAg laboratory report documented in the infant's medical record.

#### After the birth dose

- The riegB series should be completed with either monovalent riegB or a combination vocatine containing regB. The second does should be administered at age 1-2 months. The final cose should be administered at age 234 weeks. Infants born to HBSA-positive mothers should be leated for HBSA and antiboot to HBSAg after completion of 20 does of a licensed HeBB series, at age 9-18 months (generality at the next weichnik vich).
- 4-month dose:
- It is permissible to administer 4 doses of HepB when combination vaccines are administered after the birth dose. If monovalent HepB is used for doses after the birth dose, a dose at are 4 months is not needed.
- Rotavirus vaccine (Rota). (Minimum age: 6 weeks)
   Administer the first doce at age 6–12 weeks. Do not start the series later than
- Administer the final dose in the series by age 32 weeks. Do not administer a
- dose later than age 32 weeks.
- Data on safety and efficacy outside of these age ranges are insufficient.
   Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (Minimum age: 6 weeks)
- The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose.
   Administer the final dose in the series at age 4–6 years.
- Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum age: 6 weeks)
   If PRP-OMP (PedvaxHIB<sup>®</sup> or ComVax<sup>®</sup> (Mercik) is administered at ages 2 and
- If PRP-OMP (PedvaxHB® or ComVax® [Merok]) is administered at ages 2 and 4 months, a dose at age 6 months is not required.
- TriHiBit<sup>®</sup> (DTaPIHib) combination products should not be used for primary immunization but can be used as boosters following any Hib vaccine in children aged <u>>12</u> months.

The Recommended Immunization Schedules for Persons Aged 0–18 Years are approved by the Advisory Committee on Immunization Practices (http://www.ado.gov/nip/acip), the American Academy of Pediatrics (http://www.aap.org), and the American Academy of Family Physicians (http://www.aafp.org).

of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices statement for detailed recommendations. Clinically significant adverse events that tolow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Suitance about how to obtain and complete a VAERS form is available at http://www.vaers. hh.s.gov or by teepones.80-42-7987.

- Pneumococcal vaccine. (Minimum age: 6 weeks for pneumococcal conjugate vaccine (PCV): 2 years for pneumococcal polycaccharide vaccine (PPV))
   Administer PCV at ages 24-59 months in certain high-risk groups. Administer PPV to children aged ≥2 years in certain high-risk groups. Ede MMWR
- 2000;49(No. RR-9);1-35. 6. Influenza vaocine. (Minimum age: 6 months for trivalent inactivated influenza vaocine (TIV); 5 years for live, attenuated influenza vaocine (LAIV)) + All children aged 8-59 months and close contacts of all children aged
- All children aged 6–59 months and close contacts of all children aged 0–59 months are recommended to receive influenza vaccine.
- Influenza vaccine is recommended annually for children aged ≥59 months with certain risk factors, health-care workers, and other persons (including household members) in close contact with persons in groups at high risk. See MMWR 2006/55/No. RR-10:1-41.
- For healthy persons aged 5–49 years, LAIV may be used as an alternative to TIV.
   Ohlidren receiving TIV should receive 0.25 mL if aged 6–35 months or 0.5 mL if aged 3.9 years.
- Children aged <9 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by 24 weeks for TNV and 26 weeks for LAV).
   Messles, mumps, and rubella vaccine (MMR), (Minimum age: 12 monitor)
- Administratine second doce of MMR at age 4–6 years. MMR may be administered before age 4–6 years, provided ≥4 weeks have elapsed since the first dose and both doces are administered at age ≥12 months.
- Administration the second does of varicetal vaccine at age 4–6 years. Varicetal vaccine may be administreed before age 4–6 years, provided that 25 months have elapsed since the first does and both does are administreed at age 21° months. If second does was administreed 226 days following the first dose, the second does does not need to be repeated.
- Hepatitis A vaccine (HepA). (Minimum age: 12 months)
   HepA is recommended for all initizen aged types (Le., aged 12–23 months). The 2 doces in the series should be administered at least 6 months apart.
   Onlidem not fully vaccinated by age 2 years can be vaccinated at budgequet visits.
   HepA is recommended for certain other groups of onlidem, Instuding In areas where vaccination programs target obser children and MMVP 2005/SNO, RR-71-12-3
- Meningococcal polysaccharide vaccine (MPSV4). (Minimum age: 2 years)
   Administer MPSV4 to children aged 2–10 years with terminal complement deficiencies or anatomic or functional aspienia and certain other high-risk groups. See MMWR 2005;54(No. Re-7):1–21.

FIGURE 2. Recommended immunization schedule for persons aged 7–18 years - United States, 2007

Vaccine ▼ Age ►	7–10 years	11-12 YEARS	13–14 years	15 years	16–18 years	-
Tetanus, Diphtheria, Pertussis <sup>1</sup>	See footnote 1	Tdap		Tdap		Range of
Human Papillomavirus <sup>2</sup>	See footnote 2	HPV (3 doses)		<b>HPV</b> Series	5	recommended
Meningococcal <sup>a</sup>	MPSV4	MCV4		MCV4 <sup>2</sup> MCV4		ages
	MP5V4			MCV4		
Pneumococcal <sup>4</sup>		PPV				
Influenza <sup>s</sup>		Influenza (Yearly)				Catch-up
Hepatitis A <sup>s</sup>		HepA Series				immunization
Hepatitis B <sup>7</sup>		HepB Series				
Inactivated Poliovirus <sup>8</sup>		IPV Series				O L. I.
Measles, Mumps, Rubella <sup>9</sup>		MMR Series				Certain high-risk
Varicella <sup>10</sup>		Varicella Series				groups

This schedule indicates the recommended ages for routine administration of currently licenses childrood vaccines, as of December 1, 2006, for children aged 7–18 yeats. Additional information is available at http://www.odc.gov/in/precisionilo-schedule.htm. Any dose not administered at the recommended age should be administered at any subsequent visik, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components of the components of the combination are indicated and other components of the combination and the components of the combination and the components of the combination and the components of the combination are indicated and there components of the combination are indicated and there components of the combination are indicated and there components of the combination are of the components of the combination are indicated and there components of the combination are indicated and there components of the combination are observed.

- Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap). (Minimum age: 10 years for BOOSTRIX<sup>®</sup> and 11 years for ADACEL<sup>®</sup>)
   Administer at age 11-12 years for those who have complete the recommended childhood DTP/DTaP vacoination series and have not received a tetanus and diphtheris toxoids vaccine (Td) bacoter doce.
- Adolescents aged 13–18 years who missed the 11–12 year Tdi/Tdap booster dose should also receive a single dose of Tdap if they have completed the recommended childhood DTP/DTaP vaccination series.
   Human papiliomavirus vaccine (HPV), (*klinimum age: 9 years*)
- Administer the first dose of the HPV vaccine series to females at age 11–12 years
- Administer the second dose 2 months after the first dose and the third dose 6 months after the first dose.
   Administer the HV vaccine series to females at ace 13–18 years if not previously
- vaccinated.
  3. Meningococcal vaccine. (Minimum age: 11 years for meningococcal conjugate
- vaccine (MOV4): 2 years for meningococcal polysaccharide vaccine (MPSV4))
   Administer MOV4 at age 11–12 years and to previously unvaccinated adolescents at high school entry (at approximately age 15 years).
- Administer MCV4 to previously unvaccinated college freshmen living in dominiories; MPSV4 is an acceptable alternative.
   Vaccination against invasive meningococcal disease is recommended for children and adolescents aged >2 vears with terminal complement deficiencies or
- anatomic or functional asplenia and certain other high-risk groups. See MMWR 2005;54(No. RR-7):1-21. Use MPSV4 for children aged 2–10 years and MOV4 or MPSV4 for older children. 4. Pneumococcal polysaccharide vascine (PPV). (Minimum age: 2 years)
- Administer for certain high-risk groups. See MMWR 1997;46(No. RR-8):1–24, and MMWR 2000:49(No. RR-9):1–35.
- Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine (TIV): 5 years for live, attenuated influenza vaccine (LAIV))
- Influenza vaccine is recommended annually for persons with certain risk factors, nealth-care workers, and other persons (including household members) in close contact with persons in groups at high risk. See MMWR 2008;55 (No. RR-10):1-41.
- (receiver healty) persons aged 5–49 years, LAIV may be used as an alternative to TIV.
- Children aged <9 years who are receiving innuenza vaccine for the first time should receive 2 doses (separated by ≥4 weeks for TIV and ≥6 weeks for LAIV).

of the vaceine are not contraindcated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Oommittee on Immunization Practices statement for detailed recommendations. Clinically significant doverse events that blow immunization should be reported to the Vaceine Adviser Event Reporting System (VAERS). Suidance about how to obtain and complete a VAERS form is available at http://www.vaers. hhs.cov.or by telenome.com.ceta.27467.

6. Hepatitis A vaccine (HepA). (Minimum age: 12 months)

- The 2 doses in the series should be administered at least 6 months apart.
   HepA is recommended for certain other groups of children, including in areas where vaccination programs target older children. See MMWR 2006;55 (No. RR-7):1–23.
- 7. Hepatitis B vaccine (HepB). (Minimum age: birth)
- Administer the 3-dose series to those who were not previously vaccinated.
   A 2-dose series of Recombivax HB<sup>®</sup> is licensed for children aged 11-5 years.
   Inectivated policivity vaccine (IPV). (Minimum age: 8 weeks)
- For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if the third dose was administered at age 24 years.
   If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's ourrent age.
- Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
   If not previously vaccinated, administer 2 doses of MMR during any visit, with
- ≥4 weeks between the doses.
  10. Varicella vaccine. (Minimum age: 12 months)

 Administer 2 doses of varicella vaccine to persons without evidence of immunity.
 Administer 2 doses of varicella vaccine to persons aged ≤13 years at least 3 months apart. Do not repeat the second dose, if administered ≥28 days after the first dose.

 Administer 2 doses of varicella vaccine to persons aged ≥13 years at least 4 weeks apart.

The Recommended Immunization Schedules for Persons Aged 0–18 Years are approved by the Advisory Committee on Immunization Practices (http://www.adp.gov/hip/acip), the American Academy of Pediatrics (http://www.aap.org), and the American Academy of Pamily Physicians (http://www.aafp.org).

# 2011 Vaccination Schedule

	Vaccine 🔻	Age►	Birth	1 month	2 months	4 months	6 months	12 months	15 months	18 months	19-23 months	2–3 years	4-6 years	
	Hepatitis B <sup>1</sup>		HepB	He	pВ			He	рВ					
ľ	Rotavirus <sup>2</sup>				RV	RV	RV <sup>2</sup>							Range of recommended
ĺ	Diphtheria, Tetanus,	Pertussis <sup>3</sup>			DTaP	DTaP	DTaP	see footnote <sup>3</sup>	DI	TaP			DTaP	ages for all
	Haemophilus influen.	zae type b <sup>4</sup>			Hib	Hib	Hib <sup>4</sup>	H	ib					children
ľ	Pneumococcal <sup>5</sup>				PCV	PCV	PCV	P	ĊV			PP	sv	
	Inactivated Polioviru	s <sup>6</sup>			IPV	IPV			v				IPV	
	Influenza <sup>7</sup>								Infl	uenza (Ye				Range of recommended
	Measles, Mumps, Ru	bella <sup>8</sup>							MR		ee footnote		MMR	ages for certain high-risk groups
	Varicella <sup>9</sup>								cella	\$	ee footnote	9	Varicella	
[	Hepatitis A <sup>10</sup>								HepA (	2 doses)			Series	
	Meningococcal <sup>11</sup>												CV4	

Vaccine ▼ Age ►	7–10 years	11–12 years	13–18 years	
Tetanus, Diphtheria, Pertussis <sup>1</sup>		Tdap	Tdap	
Human Papillomavirus <sup>2</sup>	see footnote <sup>2</sup>	HPV (3 doses)(females)	HPV series	Range of recommend
Meningococcal <sup>3</sup>	MCV4	MCV4	MCV4	ages for all children
Influenza <sup>4</sup>		Influenza (Yearly)		
Pneumococcal <sup>5</sup>		Pneumococcal		Range of recom-
Hepatitis A <sup>6</sup>		HepA Series		mended age for catch-up
Hepatitis B <sup>7</sup>		Hep B Series	•	immunizatio
Inactivated Poliovirus <sup>8</sup>		IPV Series		
Measles, Mumps, Rubella <sup>9</sup>		MMR Series		Range of recommend
Varicella <sup>10</sup>		Varicella Series		ages for cert high-risk gro

Vaccine <b>V</b>	Age►	Birth	1 month	2 months	4 months	6 months	9 months	12 months	15 months	18 months	19–23 months	2–3 years	4–6 years	Range of
Hepatitis B <sup>1</sup>		HepB	He	рВ				HepB						recomment ages for all
Rotavirus <sup>2</sup>				RV	RV	RV <sup>2</sup>								children
Diphtheria, tetanus,	pertussis <sup>3</sup>			DTaP	DTaP	DTaP		Seefootnote	D	TaP			DTaP	
Haemophilus influen	<i>zae</i> type b <sup>4</sup>			Hib	Hib	Hib⁴		н	ib					Range of
Pneumococcal⁵				PCV	PCV	PCV		PC	v			PP	sv	recommen ages for ce
Inactivated polioviru	15 <sup>6</sup>			IPV	IPV			IPV					IPV	high-risk g
Influenza <sup>7</sup>									Influenz	a (yearly)				///
Measles, mumps, ru	bella <sup>8</sup>							M	MR		See footnote		MMR	Range of
Varicella <sup>9</sup>								VA	AR		See footnote		VAR	recommer ages for al children ar
Hepatitis A <sup>10</sup>									Dos	e 1 <sup>10</sup>		/ HepA	series /	certain hig
Meningococcal <sup>11</sup>									MCV4	— See foo	tnote 11			groups

Vaccine 🔻	Age►	7–10 years	11–12 years	13–18 years						
Tetanus, diphtheria	, pertussis <sup>1</sup>	1 dose (if indicated)	1 dose	1 dose (if indicated)	Range of recommended					
Human papillomav	rirus <sup>2</sup>	See footnote <sup>2</sup>	3 doses	Complete 3-dose series	ages for all children					
Meningococcal <sup>3</sup>		See footnote <sup>3</sup>	Dose 1	Booster at age 16 years						
Influenza <sup>4</sup>			Influenza (yearly)							
Pneumococcal <sup>5</sup>			See footnote <sup>5</sup>							
Hepatitis A <sup>6</sup>			See footnote <sup>2</sup> See footnote <sup>3</sup> Dose 1 Booster at age 16 years Influenza (yearly)							
Hepatitis B <sup>7</sup>			See footnote <sup>3</sup> Dose 1     Booster at age 16 years       Influenza (yearly)     See footnote <sup>5</sup> Complete 2-dose series     Complete 3-dose series							
Inactivated poliovi	rus <sup>8</sup>		Complete 3-dose series							
Measles, mumps, r	ubella <sup>9</sup>		Complete 2-dose series		Range of recommended					
Varicella <sup>10</sup>			Complete 2-dose series		ages for certain high-risk groups					

#### Figure 1. Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2018.

#### (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]).

These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded in gray.

Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19-23 mos	2-3 yrs	4 <b>-</b> 6 yrs	7-10 yrs	11 <b>-</b> 12 yrs	13-15 yrs	16 yrs	17 <b>-</b> 18 yrs
Hepatitis B <sup>7</sup> (HepB)	1 <sup>st</sup> dose	<b>≺</b> 2 <sup>nd</sup> (	dose ·····>		<b>-</b>		3 <sup>rd</sup> dose		>								
Rotavirus <sup>2</sup> (RV) RV1 (2-dose series); RV5 (3-dose series)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See footnote 2												
Diphtheria, tetanus, & ace <b>llul</b> ar pertussis <sup>3</sup> (DTaP: <7 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose			<b>≪</b> 4 <sup>th</sup> (	lose>			5 <sup>th</sup> dose					
Haemophilus influenzae type b⁴ (Hib)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See footnote 4			<sup>th</sup> dose, <b>&gt;</b> tnote 4									
Pneumococcal conjugate⁵ (PCV13)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose		<b>≺</b> 4 <sup>th</sup> c	lose>							 		
Inactivated poliovirus⁵ (IPV: <18 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	<b></b>		3 <sup>rd</sup> dose		>			4 <sup>th</sup> dose					
Influenza <sup>7</sup> (IIV)							l An	nual vaccina	ution ( <mark>II</mark> V) 1 c	or 2 doses				Ar	nua <mark>l</mark> vaccina 1 dose o		
Measles, mumps, rubella <sup>®</sup> (MMR)					See foo	tnote 8	<b>≺</b> 1 <sup>st</sup> d	lose>				2 <sup>nd</sup> dose					
Varice <b>ll</b> a <sup>9</sup> (VAR)							<b>≺</b> 1¤d	lose>				2 <sup>nd</sup> dose					
Hepatitis A <sup>10</sup> (HepA)							<mark>&lt;2-c</mark>	lose series, S	see footnote	10>							
Meningococcal <sup>11</sup> (MenACWY-D ≥9 mos; MenACWY-CRM ≥2 mos)						See foo	tnote 11							1 <sup>st</sup> dose		2 <sup>nd</sup> dose	
Tetanus, diphtheria, & acellular pertussis™ (Tdap: ≥7 yrs)														Tdap			
Human papi <b>ll</b> omavirus¹⁴ (HPV)														See footnote 14			
Meningococcal B <sup>12</sup>															See footr	note 12	
Pneumococcal polysaccharide <sup>5</sup> (PPSV23)													S	ee footnote	5		
Range of recommended ages for all children			of recomme ch-up immu			Range for ce	e of recomn rtain high-r	nended age isk groups	s	grou	ge of recom ps that may idual clinic	/ receive va	es for non-ł ccine, subje making	nigh-risk ct to		No recom	mendatio

NOTE: The above recommendations must be read along with the footnotes of this schedule.